Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A retrospective evaluation of the role of T cells in the development of malaria vaccine.

Literature DB >> 19944099

A retrospective evaluation of the role of T cells in the development of malaria vaccine.

Abstract

Due to the fact that the life cycle of malaria parasites is complex, undergoing both an extracellular and intracellular phases in its host, the human immune system has to mobilize both the humoral and cellular arms of immune responses to fight against this parasitic infection. Whereas humoral immunity is directed toward the extracellular stages which include sporozoites and merozoites, cell-mediated immunity (CMI), in which T cells play a major role, targets hepatic stages - liver stages - of the parasites. In this review, the role of T cells in protective immunity against liver stages of the malaria infection is being re-evaluated. Furthermore, this review intends to address how to translate the findings regarding the role of T cells obtained in experimental systems to actual development of malaria vaccine for humans. (c) 2009 Elsevier Inc. All rights reserved.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Malaria Vaccines

Year: 2009 PMID： 19944099 PMCID： PMC3603350 DOI： 10.1016/j.exppara.2009.11.009

Source DB: PubMed Journal: Exp Parasitol ISSN： 0014-4894 Impact factor: 2.011

54 in total

1. Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein.

Authors: Y Takita-Sonoda; M Tsuji; K Kamboj; R S Nussenzweig; P Clavijo; F Zavala
Journal: Exp Parasitol Date: 1996-11 Impact factor: 2.011

2. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages.

Authors: L Rénia; D Grillot; M Marussig; G Corradin; F Miltgen; P H Lambert; D Mazier; G Del Giudice
Journal: J Immunol Date: 1993-02-15 Impact factor: 5.422

3. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.

Authors: R Wang; Y Charoenvit; G Corradin; P De La Vega; E D Franke; S L Hoffman
Journal: J Immunol Date: 1996-11-01 Impact factor: 5.422

4. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors: D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal: Infect Immun Date: 1996-05 Impact factor: 3.441

5. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria.

Authors: M Rodrigues; R S Nussenzweig; F Zavala
Journal: Immunology Date: 1993-09 Impact factor: 7.397

6. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity.

Authors: D L Doolan; M Sedegah; R C Hedstrom; P Hobart; Y Charoenvit; S L Hoffman
Journal: J Exp Med Date: 1996-04-01 Impact factor: 14.307

7. The role of CD4+ T cells in immunity to malaria sporozoites.

Authors: W R Weiss; M Sedegah; J A Berzofsky; S L Hoffman
Journal: J Immunol Date: 1993-09-01 Impact factor: 5.422

8. Development of antimalaria immunity in mice lacking IFN-gamma receptor.

Authors: M Tsuji; Y Miyahira; R S Nussenzweig; M Aguet; M Reichel; F Zavala
Journal: J Immunol Date: 1995-05-15 Impact factor: 5.422

9. MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei.

Authors: K L White; H L Snyder; U Krzych
Journal: J Immunol Date: 1996-05-01 Impact factor: 5.422

10. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells.

Authors: M C Seguin; F W Klotz; I Schneider; J P Weir; M Goodbary; M Slayter; J J Raney; J U Aniagolu; S J Green
Journal: J Exp Med Date: 1994-07-01 Impact factor: 14.307

18 in total

Review 1. Large screen approaches to identify novel malaria vaccine candidates.

Authors: D Huw Davies; Patrick Duffy; Jean-Luc Bodmer; Philip L Felgner; Denise L Doolan
Journal: Vaccine Date: 2015-10-01 Impact factor: 3.641

Review 2. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors: Neal N Padte; Xiangming Li; Moriya Tsuji; Sandhya Vasan
Journal: Clin Immunol Date: 2010-12-24 Impact factor: 3.969

3. A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.

Authors: Takayuki Shiratsuchi; Urvashi Rai; Izumi Kaneko; Min Zhang; Shiroh Iwanaga; Masao Yuda; Moriya Tsuji
Journal: Vaccine Date: 2017-10-28 Impact factor: 3.641

4. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites.

Authors: Noah S Butler; Nathan W Schmidt; Ashley M Vaughan; Ahmed S Aly; Stefan H I Kappe; John T Harty
Journal: Cell Host Microbe Date: 2011-06-16 Impact factor: 21.023

5. CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay.

Authors: Jing Zhou; Alaina Kaiser; Colin Ng; Rachel Karcher; Tim McConnell; Patrick Paczkowski; Cristina Fernandez; Min Zhang; Sean Mackay; Moriya Tsuji
Journal: Hum Vaccin Immunother Date: 2017-07-03 Impact factor: 3.452